Transneural Therapeutics

Actual: Apr 22, 2025

Transneural Therapeutics spun out of CaaMTech to develop non-hallucinogenic neuroplastogens. CEO: Charmaine Lykins (30+ years CNS pharma; CCO at Karuna/BMS, CMO at ACADIA; launched COBENFY, NUPLAZID, REXULTI, LATUDA, CYMBALTA, ZYPREXA).

Why it matters: Dedicated company with best-in-class CNS leadership. Lykins' track record of 10 CNS product launches including recent Karuna/BMS COBENFY gives Transneural credibility for regulatory execution. CaaMTech retains hallucinogenic pipeline (CT-4201) while Transneural gets non-hallucinogenic neuroplastogens.

Actual: Apr 29, 2025

Mark A. Demitrack, MD appointed Chief R&D Officer. 30+ years neuropsychiatry; former CMO at Trevena and Neuronetics (led NeuroStar TMS launch); led Cymbalta NDA at Eli Lilly; 100+ publications; Fellow of APA, member ACNP.

Why it matters: Demitrack's NDA experience (Cymbalta, one of the world's top-selling antidepressants) is exactly the regulatory profile needed to take TN-001 from IND through Phase 3. His ACNP membership provides direct access to the clinical trial investigator network.

Actual: Jan 14, 2026

Preclinical data presented at ACNP 2026 (Nassau, Bahamas): (1) In vitro — TN-001 induces statistically significant dose-dependent structural neuroplasticity in rat neuronal cultures: increased neuron count, synapse formation, and neurite network expansion. (2) In vivo (efficacy) — reduced immobility in forced swim test (antidepressant phenotype). (3) In vivo (safety) — no head-twitch response (absent hallucinogenic properties), no locomotor impairment at therapeutic doses.

Why it matters: Comprehensive preclinical package demonstrates the triple differentiation: neuroplasticity (efficacy), antidepressant phenotype (behavioral), and safety (non-hallucinogenic, no motor impairment). 5-HT2B antagonism specifically mitigates cardiac valvulopathy risk — a concern with chronic serotonergic compounds like fenfluramine. This data package is core to the IND filing.